MedTrace Logo

AG-120 in People With IDH1 Mutant Chondrosarcoma

NCT04278781 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-04-23

No results posted yet for this study

Summary

This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

Conditions

  • Chondrosarcoma
  • Chondrosarcoma, Grade 2
  • Chondrosarcoma, Grade 3
  • IDH1 Gene Mutation

Interventions

DRUG

AG-120

AG-120 500 mg orally once daily days 1-28 of a 28-day cycle

Sponsors & Collaborators

Principal Investigators

  • Ciara M Kelly, MBBCh, BAO · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-04
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04278781 on ClinicalTrials.gov